PHILIP SALTIEL: Open Payments
NPI 1710972948 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,006 in 102 payments from 18 companies in 2025. Trend: 2023 $2,110 · 2024 $2,362 · 2025 $2,006
Food & beverage: $2,006
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 20 | $332 |
| Axsome Therapeutics, Inc. | 13 | $224 |
| Bausch Health US, LLC | 9 | $223 |
| ABBVIE INC. | 9 | $212 |
| E.R. Squibb & Sons, L.L.C. | 7 | $166 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 5 | $87 |
| Janssen Pharmaceuticals, Inc | 4 | $82 |
| Teva Pharmaceuticals USA, Inc. | 4 | $81 |
Products named: REXULTI, VRAYLAR, COBENFY, WELLBUTRIN, ABILIFY ASIMTUFII, Auvelity, CAPLYTA, TRINTELLIX.
Industry payments across NY — which companies pay providers there.
